Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models

European Journal of Pharmacology

Volumn 512, Issue 2-3, 2005, Pages 239-246

  Nakamura, Hiroaki ^a   Inoue, Tatsuya ^a   Arakawa, Naohisa ^a   Shimizu, Yuki ^a   Yoshigae, Yasushi ^a   Fujimori, Izumi ^a   Shimakawa, Emi ^a   Toyoshi, Tohru ^b   Yokoyama, Tomihisa ^a  

^a DAIICHI SANKYO CO   (Japan)

^b Nihon Bioresearch Inc   (Japan)

Author keywords

Angiotensin; Diabetic retinopathy; Electroretinogram; Olmesartan medoxomil; Oxygen induced retinopathy

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; OLMESARTAN; OXYGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; ELECTRORETINOGRAPHY; EXPERIMENTAL MODEL; IC 50; IN VITRO STUDY; MALE; NONHUMAN; OSCILLATORY POTENTIAL; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; RAT STRAIN; RETINA NEOVASCULARIZATION; STATISTICAL SIGNIFICANCE;

EID: 17444373141     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.02.047     Document Type: Article

References (29)

1. L.P. Aiello, E.A. Pierce, E.D. Foley, H. Takagi, H. Chen, L. Riddle, N. Ferrara, G.L. King, and L.E. Smith Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins Proc. Natl. Acad. Sci. U. S. A. 92 1995 10457 10461
2. American Diabetes Association Diabetic retinopathy Diabetes Care 23 2000 S73 S76
3. N. Chaturvedi, A.K. Sjolie, J.M. Stephenson, H. Abrahamian, M. Keipes, A. Castellarin, Z. Rogulja-Pepeonik, and J.H. Fuller Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB controlled trial of Lisinopril in Insulin-Dependent Diabetes Mellitus Lancet 351 1998 28 31
4. A. Cosenzi, E. Bocin, A. Sacerdote, N. Plazzotta, P. Seculin, E. Bernobich, N. Solimano, G. Ravalico, and G. Bellini Antihypertensive drugs and the nervous system: ACE-inhibitors restore oscillatory potentials in hypertensives Clin. Exp. Hypertens. 21 1999 223 231
5. Early Treatment Diabetic Retinopathy Study Research Group Early photocoagulation for diabetic retinopathy. ETDRS report number 9 Ophthalmology 98 1991 766 785
6. R.E. Gilbert, D.J. Kelly, A.J. Cox, J.L. Wilkinson-Berka, J.R. Rumble, T. Osicka, S. Panagiotopoulos, V. Lee, E.C. Hendrich, G. Jerums, and M.E. Cooper Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes Diabetologia 43 2000 1360 1367
7. R. Klein, B.E. Klein, S.E. Moss, M.D. Davis, and D.L. DeMets The Wisconsin epidemiologic study of diabetic retinopathy: II. Prevalence risk of diabetic retinopathy when age at diagnosis is less than 30 years Arch. Ophthalmol. 102 1984 520 526
8. H. Koike New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist Am. J. Cardiol. 87 2001 33C 36C
9. N. Kurikawa, M. Suga, S. Kuroda, K. Yamada, and H. Ishikawa An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells Br. J. Pharmacol. 139 2003 1085 1094
10. M. Lonchampt, L. Pennel, and J. Duhault Hyperoxia/normoxia-driven retinal angiogenesis in mice: a role for angiotensin II Invest. Ophthalmol. Visual Sci. 42 2001 429 432
11. G.A. Lutty, and D.S. McLeod A new technique for visualization of the human retinal vasculature Arch. Ophthalmol. 110 1992 267 276
12. M. Mizuno, T. Sada, M. Ikeda, N. Fukuda, M. Miyamoto, H. Yanagisawa, and H. Koike Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist Eur. J. Pharmacol. 285 1995 181 188
13. M. Mizuno, T. Sada, M. Kato, and H. Koike Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes Hypertens. Res. 25 2002 271 278
14. Y. Nagisa, A. Shintani, and S. Nakagawa The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats Diabetologia 44 2001 883 888
15. M. Nangaku, T. Miyata, T. Sada, M. Mizuno, R. Inagi, Y. Ueda, N. Ishikawa, H. Yuzawa, H. Koike, C. van Ypersele de Strihou, and K. Kurokawa Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model J. Am. Soc. Nephrol. 14 2003 1212 1222
16. J.M. Neutel, W.J. Elliott, J.L. Izzo, C.L. Chen, and H.N. Masonson Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements J. Clin. Hypertens. (Greenwich) 4 2002 325 331
17. A. Otani, H. Takagi, K. Suzuma, and Y. Honda Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells Circ. Res. 82 1998 619 628
18. A. Otani, H. Takagi, H. Oh, K. Suzuma, M. Matsumura, E. Ikeda, and Y. Honda Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes Invest. Ophthalmol. Visual Sci. 41 2000 1192 1199
19. H. Ozaki, M.S. Seo, K. Ozaki, H. Yamada, E. Yamada, N. Okamoto, F. Hofmann, J.M. Wood, and P.A. Campochiaro Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization Am. J. Pathol. 156 2000 697 707
20. H.H. Parving, M. Larsen, E. Hommel, and H. Lund-Andersen Effect of antihypertensive treatment on blood-retinal barrier permeability to fluorescein in hypertensive type 1 (insulin-dependent) diabetic patients with background retinopathy Diabetologia 32 1989 440 444
21. L.R. Schwocho, and H.N. Masonson Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects J. Clin. Pharmacol. 41 2001 515 527
22. Y. Segawa, Y. Shirao, S. Yamagishi, T. Higashide, M. Kobayashi, K. Katsuno, A. Iyobe, H. Harada, F. Sato, H. Miyata, H. Asai, A. Nishimura, M. Takahira, T. Souno, Y. Segawa, K. Maeda, K. Shima, A. Mizuno, H. Yamamoto, and K. Kawasaki Upregulation of retinal vascular endothelial growth factor mRNAs in spontaneously diabetic rats without ophthalmoscopic retinopathy. A possible participation of advanced glycation end products in the development of the early phase of diabetic retinopathy Ophthalmic Res. 30 1998 333 339
23. L.E. Smith, E. Wesolowski, A. McLellan, S.K. Kostyk, R. D'Amato, R. Sullivan, and P.A. D'Amore Oxygen-induced retinopathy in the mouse Invest. Ophthalmol. Visual Sci. 35 1994 101 111
24. M. Tadesse, Y. Yan, P. Yossuck, and R.D. Higgins Captopril improves retinal neovascularization via endothelin-1 Invest. Ophthalmol. Visual Sci. 42 2001 1867 1872
25. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N. Engl. J. Med. 329 1993 977 986
26. The Diabetic Retinopathy Vitrectomy Study Research Group Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial-Diabetic Retinopathy Vitrectomy Study Report 3 Ophthalmology 95 1988 1307 1320
27. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 317 1998 703 713
28. D. Yonemura, T. Aoki, and K. Tsuzuki Electroretinogram in diabetic retinopathy Arch. Ophthalmol. 68 1962 19 24
29. S. Zhang, D.A. Leske, and J.M. Holmes Neovascularization grading methods in a rat model of retinopathy of prematurity Invest. Ophthalmol. Visual Sci. 41 2000 887 891